CareDx Inc (CDNA)vsThermo Fisher Scientific Inc (TMO)
CDNA
CareDx Inc
$47.31
+0.17%
HEALTHCARE · Cap: $2.35B
TMO
Thermo Fisher Scientific Inc
$605.00
-0.33%
HEALTHCARE · Cap: $208.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 10015% more annual revenue ($46.34B vs $458.09M). CDNA leads profitability with a 24.2% profit margin vs 15.0%. CDNA trades at a lower P/E of 22.6x. TMO earns a higher WallStSmart Score of 60/100 (C+).
CDNA
Buy53
out of 100
Grade: C-
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.3%
Fair Value
$62.15
Current Price
$47.31
$14.84 discount
Margin of Safety
-75.8%
Fair Value
$344.16
Current Price
$605.00
$260.84 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 52.2% year-over-year
Conservative balance sheet, low leverage
Keeps 24 of every $100 in revenue as profit
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
0.0% earnings growth
Operating margin of 0.2%
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.2% and operating margin at 0.2%. Revenue growth of 52.2% demonstrates continued momentum.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Operating Margin, Return on Equity.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CDNA profiles as a growth stock while TMO is a value play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.42 — expect wider price swings.
CDNA is growing revenue faster at 52.2% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 53/100) and 10.5% revenue growth. CDNA offers better value entry with a 68.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?